Clinical Trial Update: To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Telitacicept in combination with standard treatment for IgA nephropathy, with status currently ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• Telitacicept

Snippet

Sponsor: The Affiliated Hospital of Xuzhou Medical University | Conditions: IgA Nephropathy (IgAN) | Phase 3 | Status: ACTIVE_NOT_RECRUITING